According to the results of KEYNOTE-024 phase III clinical trial, if NSCLC patients bear PD-L1 expression upon at least 50% of cancer cells, pembrolizumab, rather than chemotherapy, is to be used as the first-line treatment (12). This evidence concerns the gene CD274 and cancer.